tbuckley/cabot-search huggingface dataset:
Do <sup>18</sup>F-FDG SUVmax ratios of metastatic to primary adenocarcinoma lesions of the lungs correlate with the patients survival times?: A PET/CT and <sup>18</sup>F- FDG imaging study.
Authors: Sam Belakhlef, CLifford Church, Jose Tongol, Jani Chirag, Jay McAfee, Sami Augustine Belakhlef, Sailaja Gadde, Suresh Lakhanpal
Journal: Journal of Clinical Oncology (2015)

e19106 Background: Investigate the possibility of existence of a correlation between 18F-FDG maximum standard uptake value (SUVmax) ratios of metastatic to primary lung lesions and survival time in patients diagnosed with adenocarcinoma using PET/CT and 18F-FDG imaging. Methods: Twenty three consecutive patients with newly diagnosed adenocarcinoma of the lung (14 males, 9 females; mean ± SD age 68.9 ± 11.2 y, range 52-88 y) who had a PET/CT and 18F-FDG scan that showed metastases were included in this research. The survival time of each patient was calculated as the elapsed time between the patient’s first contact with our cancer center and his/her expiration. All patients received an 18F-FDG dose proportional to their body weights (5.2 MBq/kg) and scanned, eyes to mid-thighs, at 50-60 min. post-injection using a GE Discovery STE 16 slices scanner in 3D mode. The PET/CT and 18F-FDG images were reviewed for abnormal tracer uptake and all hypermetabolic lesions had their SUVmax calculated. Results: The average survival time (mean ± SD) was 0.8 ± 0.6 y, range 0.1-2.5 y. The average SUVmax for metastatic and primary lung adenocarcinoma tumors were: 5.0 ± 3.3 and 11.8 ± 4.8 respectively. Also, the patients’ survival times were graphed as a function of the 18F-FDG SUVmax ratios of metastases to primary lung lesions. The best fitting curve to these data points, correlation coefficient R = 0.72, was found to be of negative logarithmic form with the equation Y = -0.47*ln(x) + 0.60. Conclusions: Although the population sample of this research is relatively small and a larger data group is needed to confirm these findings, its results show the existence of a correlation between SUVmax ratios of metastases to primary adenocarcinoma of lung lesions and the patients’ survival times. This research also showed the possibility of modeling the above data by a negative logarithmic function.
Abstract 11766: Long Term Follow-up and Outcome of Atrial Fibrillation Patients With Left Atrial Appendage Obliteration Using Wireless Absorbable Occluders
Authors: Eleftherios Sideris, Savvas Toumanides, Tullio Agricola, Spyridon Moulopoulos
Journal: Circulation (2016)

Introduction: Metal occluders for the left atrial appendage (LAA) have been associated with morbidity that prevents their use as a primary approach for stroke prevention, in the majority of patients with atrial fibrillation(AF). Information on their long term outcome is limited. We hypothesize that a safe and effective occluder that reduces this morbidity with good long term outcome, could potentially replace anticoagulation in all patients with AF. Methods: The Transcatheter Patch (TP) is an absorbable wireless device made by inflatable polyurethane. It was successfully implanted in the LAA for stroke prevention in 27/30 high risk for stroke patients (CHADS2 score&gt;3) from 2005-2012. The patient age varied from 28-89 years and the LAA mouth diameter from 12-24 mm. No patient received supplemental anticoagulation. The patients were followed by transesophageal echocardiography (TEE) at 1 month, 6 months and one year. They had yearly clinical follow-ups, thereafter. The results along with the clinical outcome were analyzed. Results: All 27 patients had uncomplicated implantation with full occlusion of the LAA. There was progressive decrease of the occluder size at 1 month (50% of the original), 6 months (20%) and one year (5%), maintaining the full occlusion. No new thromboembolic episodes, or other device related complications were noticed during the first year or in the subsequent clinical follow-up (max. 10, median 5 years). However, 4 deaths were noticed in this group for unrelated to AF causes (cancer, aortic aneurysm, renal failure etc). Conclusion: It appears that the wireless absorbable occluder used succeeded in preventing thromboembolic episodes with no morbidity both on early and on long term follow-up. The occurence of several unrelated to the procedure deaths in this high risk group necessitates the performance of long term trials in a lower risk group of AF patients. Providing that the favorable acute and long term results are maintained, use of the TP device for LAA closure could be preferable to anticoagulation for stroke prevention, in patients who are currently not indicated for LAA closure.
SAT-195-The novel HBx mutation F30V correlates with HCC in vivo, hampers HBV replicative efficiency and enhances anti-apoptotic activity of HBx N-terminus in vitro
Authors: Romina Salpini, Matteo Surdo, Maria Francesca Cortese, Gianna Aurora Palumbo, Luca Carioti, Giuseppina Cappiello, Alberto Spanò, Pascale Trimoulet, Hervé Fleury, Caterina Pasquazzi, Carmen Mirabelli, Rossana Scutari, Angelica Sacco, Mohammad Alkhatib, Jacopo Vecchiet, Gabriele Missale, Simona Francioso, Loredana Sarmati, Massimo Andreoni, Mario Angelico, Francesca Ceccherini Silberstein, Massimo Levrero, Carlo Federico Perno, Laura Belloni, Valentina Svicher
Journal: Journal of Hepatology (2019)
EnsurePlus as an Alternative to the Standardized Egg Gastric-Emptying Meal
Authors: Lilja B. Solnes, Sara Sheikhbahaei, Harvey A. Ziessman
Journal: Clinical Nuclear Medicine (2019)

The purpose of this study was to establish normal gastric-emptying values for EnsurePlus in healthy subjects and to determine whether it is an acceptable alternative to the recommended standardized Tc-sulfur colloid egg meal.Twenty-one healthy subjects underwent gastric-emptying scintigraphy with In-DTPA EnsurePlus. Normal gastric emptying values were established for 1, 2, 3, and 4 hours after meal ingestion. The gastric-emptying results were compared with another group of normal subjects (n = 18) who ingested the standardized egg meal.The mean (95% upper reference limit) percentages for gastric retention for EnsurePlus were as follows: 69.9% (87.1%) at 1 hour, 35.1% (64.3%) at 2 hours, 13.5% (23.2%) at 3, and 8.9% (13.5%) at 4 hours. There were time-related differences in the gastric emptying of the EnsurePlus compared with the egg meal. In the first and second hours, there were no difference between EnsurePlus and the egg meal in terms of percentage retention (P = 0.92 at 1 hour, P = 0.05 at 2 hours). However, at 3 and 4 hours after meal ingestion, the mean percentage gastric retention of the EnsurePlus was significantly higher than the egg meal (P < 0.001).EnsurePlus is a good and acceptable alternative to the standardized egg meal.
Utility of perecnt growth-rate inhibition (% GRI), a tumor growth-rate based metric to more accurately estimate response rate and magnitude of anti-tumor agents.
Authors: Dean Bottino, Ekta Kadakia, Eric H. Westin, Wen Chyi Shyu, Jing-Tao Wu, Arijit Chakravarty
Journal: Journal of Clinical Oncology (2015)

e22169 Background: Metrics such as RECIST and % Change from baseline (%CFB) are regularly used as efficacy end-points in Phase-1 to estimate response rate and establish dose-response relationships. However, these metrics do not take into consideration variables such as the intrinsic tumor growth-rate variability across patients. We propose a growth-rate based metric called % growth rate inhibition (% GRI) to more accurately estimate drug effect. In this work, we highlight the intrinsic dependencies of % CFB on clinical variables and the implication of that on the underlying dose-response relationship. Using simulations we further compare the performance of %GRI and RECIST in classifying patients for different thresholds of response. Methods: Drug effect was defined as the ratio of tumor growth rate after treatment to tumor growth rate before treatment. % GRI was calculated as 100*(1-Drug Effect). As a first step, tumor-burden time course was simulated across a population of patients with heterogeneous tumor doubling times to evaluate 1) the robustness of %CFB across a range of tumor growth rates and post-treatment collection times 2) the effectiveness of % CFB as a response-metric in establishing dose-response relationships. In the next step, simulations were performed assuming an 8.5% measurement error. Receiver operating characteristic (ROC) analysis was performed to compare the performance of %GRI and %CFB in identifying patients experiencing a specified drug effect. Results: %CFB was demonstrated to be dependent of tumor growth rate and post-treatment time. Even in the absence of any measurement noise, %CFB failed to provide an accurate estimate of drug effect and thereby confounded the underlying dose-response relationship. ROC analyses confirmed improved sensitivity and specificity of %GRI vs. RECIST to patient response. Conclusions: We demonstrate that the use of a kinetic measure improves the assessment of clinical response of anti-cancer agents. Such careful assessment of clinical anti-tumor response may in turn lead to more informed decision making for patient classification, schedule selection and biomarker selection after Phase-1.
Analysis of expression of PTEN/PI3K pathway and programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Authors: Susana Cedres Perez, Santiago Ponce Aix, Irene Sansano, Alejandro Navarro, Alex Martinez Marti, Jon Zugazagoitia, Lorena Farinas, Enrique Sanz-Garcia, Marta Vilaro, Enriqueta Felip
Journal: Journal of Clinical Oncology (2015)

e18540 Background: Malignant pleural mesothelioma (MPM) frequently expresses elevated AKT/mTOR activity. Previous reports in gliomas, colon, breast and prostate cancer suggests that PTEN/PI3K pathway may be important for the induction of PD-L1 expression. This study explored the expression of PTEN/PI3K pathway and PD-L1 in MPM and its relationship with the patient´s prognosis Methods: 27 consecutive MPM patients were collected between 2000 and 2010. Paraffin-embedded biopsies were used for immunohistochemical profile quantified through the H-score method for PTEN/PI3K pathway. Staining with anti-PD-L1 (clone E1L3N) was considered positive in cases showing more than 1% expression of PD-L1. No systemic treatment prior to obtain the tumor sample. Staining results of each antibody were compared with clinical features Results: Demographics: male/female (20/7); median age 68.4 (range 53.5-84.8 years); histology epithelial/no epithelial (19/8); PS 0/1/2 (3/21/3); stage III/IV (17/8). 20 patients were treated with chemotherapy. Median overall survival (OS) was 13 months. Expression of PTEN, mTOR, pAKT, p4EBP1, peif4E, pS6 and FOXO3a in MPM was found in 88.5%, 92.3%, 78.3%, 38.5%, 100%, 52.2% and 100% of tumors respectively. No correlations between proteins and age, performance status, stage, histology and response to chemotherapy. We found a significant correlation between peif4E, pAKT and FOXO3a expression and longer overall survival (p < 0.05).PD-L1 was positive in 23.1% p. We found differences in expression PD-L1 according to histology: PD-L1 expression was more frequent in no-epithelial tumor (57% vs 10%,p = 0.028) PD-L1 is a significant prognostic factor for OS, median survival for PD-L1 positive/negative patients was 5 vs 20 months (p = 0.009). We did not identify significant association between the level of PD-L1 expression and alterations in PI3K pathway although a trend was observed for PTEN and pmTOR (p > 0.05) Conclusions: This study shows PTEN/PI3K pathway and PD-L1 in MPM are frequently activated. PD-L1 is a negative prognostic factor for OS. With a limited number of patients, we did not observed association between PD-L1 and the involvement of the PI3K pathway in MPM.
Oral Tofacitinib Treatment of Erosive Pustular Dermatosis of the Scalp
Authors: Nicole Leung, Hysem Eldik, Mary R. Ramirez, Pooja Sodha
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
Authors: Carol Pollock, Bergur Stefánsson, Daniel Reyner, Peter Rossing, C David Sjöström, David C Wheeler, Anna Maria Langkilde, Hiddo J L Heerspink
Journal: The Lancet Diabetes & Endocrinology (2019)
FRI-060-Effects of the ileal bile acid transport inhibitor A4250 on pruritus and serum bile acids in patients with biliary atresia: phase 2 study results
Authors: Ulrich Baumann, Ekkehard Sturm, Florence Lacaille, Emmanuel Gonzales, Henrik Arnell, Björn Fischler, Marianne Hørby Jørgensen, Richard Thompson, Jan Mattsson, Per-Goran Gillberg, Kristina Torfgard
Journal: Journal of Hepatology (2019)
Letter by Hoekstra et al Regarding Article, “Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages”
Authors: Menno Hoekstra, Olga S.C. Snip, Miranda Van Eck
Journal: Circulation (2019)
THU-294-Non-invasive measures of liver fibrosis in NAFLD is associated with cardiovascular risk
Authors: David Niederseer, Sebastian Bachmayer, Andreas Stadlmayr, Ursula Huber-Schönauer, Dieter Lederer, Christian Schmied, Sabrina Hammerl, Elmar Aigner, Martin Plöderl, Wolfgang Patsch, Christian Datz
Journal: Journal of Hepatology (2019)
Abstract 12234: Obesity and Stress Testing: Insights From a 25-year Registry
Authors: Serge C Harb, Xu Bo, Yuping Wu, Paul C Cremer, Leslie Cho, Venu Menon, Wael A Jaber
Journal: Circulation (2017)

Introduction: Obesity is a major public health problem and cardiovascular risk factor. Its influence on the choice of the modality of stress testing and impact on exercise (ex.) time have not been ...
PS-130-Preclinical pharmacology of CJ-14199, a new and potent ileum bile acid transporter inhibitor for non-alcoholic steatohepatitis
Authors: Jin Woo Jung, Hyungjin Jun, Dong-Hyun Kim, Keun-Ho Lee, Ju Hyun Lee, Dong-Kyu Kim, Soo-Jin Kim, Byoung-Seok Moon, Won Kim, Shin-Young Ryu
Journal: Journal of Hepatology (2019)
Lactates and Local Knowledge — A Parable of Teamwork
Authors: Aaron L. Schwartz, Matthew F. Basilico, Jennifer L. Friedman
Journal: New England Journal of Medicine (2019)

Our patient looked bad, and his labs looked worse. We'd never seen such a high lactate level. What was going on? The diagnosis would soon emerge, along with a lesson: the different perspectives and types of expertise within our team were crucial to solving the case.
Metastatic Colorectal Cancer Rewrites Metabolic Program Through a Glut3-YAP-dependent Signaling Circuit
Authors: Chih-Chia Kuo, Hsiang-Hsi Ling, Ming-Chen Chiang, Chu-Hung Chung, Wen-Ying Lee, Cheng-Ying Chu, Yu-Chih Wu, Cheng-Hsun Chen, Yi-Wen Lai, I-Lin Tsai, Chia-Hsiung Cheng, Cheng-Wei Lin
Journal: Theranostics (2019)

Rationale: Cancer cells reprogram cellular metabolism to fulfill their needs for rapid growth and metastasis. However, the mechanism controlling this reprogramming is poorly understood. We searched for upregulated signaling in metastatic colorectal cancer and investigated the mechanism by which Glut3 promotes tumor metastasis. Methods: We compared RNA levels and glycolytic capacity in primary and metastatic colon cancer. The expression and association of Glut3 with clinical prognosis in colon cancer tissues was determined by immunohistochemistry. Glut3 gain-of-function and loss-of-function were established using colon cancer HCT116, HT29, and metastatic 116-LM cells, and tumor invasiveness and stemness properties were evaluated. Metabolomic profiles were analyzed by GC/MS and CE-TOF/MS. The metastatic burden in mice fed a high-fat sucrose diet was assessed by intravenous inoculation with Glut3 knockdown 116-LM cells. Results: Upregulation of glycolytic genes and glycolytic capacity was detected in metastatic colorectal cancer cells. Specifically, Glut3 overexpression was associated with metastasis and poor survival in colorectal cancer patients. Mechanistically, Glut3 promoted invasiveness and stemness in a Yes-associated protein (YAP)-dependent manner. Activation of YAP in turn transactivated Glut3 and regulated a group of glycolytic genes. Interestingly, the expression and phosphorylation of PKM2 were concomitantly upregulated in metastatic colorectal cancer, and it was found to interact with YAP and enhance the expression of Glut3. Importantly, a high-fat high-sucrose diet promoted tumor metastasis, whereas the inhibition of either Glut3 or YAP effectively reduced the metastatic burden. Conclusion: Activation of the Glut3-YAP signaling pathway acts as a master activator to reprogram cancer metabolism and thereby promotes metastasis. Our findings reveal the importance of metabolic reprogramming in supporting cancer metastasis as well as possible therapeutic targets.
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients
Authors: Adrian G. McNicholl, Dmitry S. Bordin, Alfredo Lucendo, Galina Fadeenko, Manuel Castro Fernandez, Irina Voynovan, Natalia Valerievna Zakharova, Aiman Silkanovna Sarsenbaeva, Luis Bujanda, Ángeles Perez-Aisa, Liudmila Vologzhanina, Oleg Zaytsev, Tatiana Ilchishina, Cristobal de la Coba, Jorge Perez Lasala, Sergey Alekseenko, Ines Modolell, Javier Molina-Infante, Rafael Ruiz-Zorrilla Lopez, Horacio Alonso-Galan, Nuria Fernandez Moreno, Jen Hinojosa, Inmaculada Santaella, Pilar Varela, Pedro Luis Gonzalez-Cordero, Jesus Barrio, Jose Luis Dominguez-Jimenez, Oscar Nuñez, Javier Alcedo, Olga P. Nyssen, Maria Caldas, Maria G. Donday, Oleg Shvetz, Francis Megraud, Colm O'Morain, Javier P. Gisbert
Journal: Clinical Gastroenterology and Hepatology (2019)
MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer
Authors: Yueh-Shan Weng, Hong-Yu Tseng, Yen-An Chen, Pei-Chun Shen, Aushia Tanzih Al Haq, Li-Mei Chen, Yi-Chung Tung, Hsin-Ling Hsu
Journal: Molecular Cancer (2019)

Triple-negative breast cancer (TNBC) is a poor prognostic breast cancer with the highest mutations and limited therapeutic choices. Cytokine networking between cancer cells and the tumor microenvironment (TME) maintains the self-renewing subpopulation of breast cancer stem cells (BCSCs) that mediate tumor heterogeneity, resistance and recurrence. Immunotherapy of those factors combined with targeted therapy or chemoagents may advantage TNBC treatment. We found that the oncogene Multiple Copies in T-cell Malignancy 1 (MCT-1/MCTS1) expression is a new poor-prognosis marker in patients with aggressive breast cancers. Overexpressing MCT-1 perturbed the oncogenic breast epithelial acini morphogenesis and stimulated epithelial-mesenchymal transition and matrix metalloproteinase activation in invasive TNBC cells, which were repressed after MCT-1 gene silencing. As mammary tumor progression was promoted by oncogenic MCT-1 activation, tumor-promoting M2 macrophages were enriched in TME, whereas M2 macrophages were decreased and tumor-suppressive M1 macrophages were increased as the tumor was repressed via MCT-1 knockdown. MCT-1 stimulated interleukin-6 (IL-6) secretion that promoted monocytic THP-1 polarization into M2-like macrophages to increase TNBC cell invasiveness. In addition, MCT-1 elevated the soluble IL-6 receptor levels, and thus, IL-6R antibodies antagonized the effect of MCT-1 on promoting M2-like polarization and cancer cell invasion. Notably, MCT-1 increased the features of BCSCs, which were further advanced by IL-6 but prevented by tocilizumab, a humanized IL-6R antibody, thus MCT-1 knockdown and tocilizumab synergistically inhibited TNBC stemness. Tumor suppressor miR-34a was induced upon MCT-1 knockdown that inhibited IL-6R expression and activated M1 polarization. The MCT-1 pathway is a novel and promising therapeutic target for TNBC.
SAT-243-Ledipasvir/sofosbuvir is highly effective and safe in patients with chronic hepatitis B virus and hepatitis C virus coinfection: Final study results
Authors: Chun-Jen Liu, Wan-Long Chuang, I-Shyan Sheen, Horng-Yuan Wang, CHIYI Chen, Kuo-Chih Tseng, Ting-Tsung Chang, Benedetta Massetto, Vithika Suri, Gregory Camus, Deyuan Jiang, Fangqiu Zhang, Anuj Gaggar, Tsung-Hui Hu, You-Chun Hsu, Gin-Ho Lo, Chi-Jen Chu, Jyh-Jou Chen, Cheng-Yuan Peng, Rong-Nan Chien, Pei-Jer Chen
Journal: Journal of Hepatology (2019)
Factors affecting progression free survival in non-HIV related classical Kaposi sarcoma.
Authors: Fatma Sen, Makbule Tambas, Rumeysa Ciftci, Bahtiyar Toz, Leyla Kilic, Hamza Ugur Bozbey, Hasan Karanlik, Sidika Kurul, Sezai Vatansever, Pinar Saip, Ahmet Kizir, Adnan Aydiner
Journal: Journal of Clinical Oncology (2015)

e20114 Background: Non-HIV related Kaposi sarcoma (NHKS) is a rare indolent neoplasm which is more common around Mediterranean origin. Data concerning factors that influence progression free survival (PFS) for NHKS are insufficient. Objective: The purpose of present retrospective analysis was to distinguish the factors affecting PFS among various subgroups of patients with NHKS. Methods: Between 1997 and 2014, 128 consecutive patients with NHKS were treated at Istanbul University Institute of Oncology. Patients were treated with local excision, laser, radiotherapy, chemotherapy, and observation. Treatment response and progression definitions were determined according to different treatment modalities administered at first line. For PFS analysis, Kaplan-Meier method was used and PFS rates of different subgroups were compared by using the log-rank test. Cox regression analysis was used for multivariate analysis of PFS. Results: At a median follow-up of 28 months, 3 patients (2.3%) died of NHKS. Of the patients, 71 (55.5%) had any progression during follow up. On univariate analysis, patients who had hypertension as a comorbid disease had statistically significant poorer PFS compared with who did not have (19±12 vs. 41±22 months; p = 0.03), whereas plaque formation was significantly associated with better outcome (25±9 vs. 54±12 months; p = 0.03). In addition, heavy smoking ( ≥ 40 pack-years) had a borderline significance regarding better PFS time (23±24 vs. 45±38 months, p = 0.06). On multivariate analysis, none of factors evaluated had any impact on PFS. Conclusions: Hypertension was significantly correlated with poorer outcome among NHKS patients. Patients with plaque formation and ≥ 40 pack-years of smoking had better PFS compared with others.
FRI-224-Reaching out to the undiagnosed people with hepatitis C infection in Belgium: A pilot study
Authors: Dana Busschots, Rob Bielen, Ozgur Koc, Eefje Dercon, Tessa Windelinckx, Griet Maertens, Stefan Bourgeois, Catharina Mathei, Geert Robaeys
Journal: Journal of Hepatology (2019)